Cellzome preclinical data

Cellzome used its Kinobeads technology to profile the interaction of 3 compounds - Sprycel dasatinib, Gleevec imatinib and SKI-606 bosutinib - with kinases and purine-binding proteins. The data, published in Nature Biotechnology, showed that the 3 compounds potentially target discoidin domain receptor kinase 1 ( DDR1), which Cellzome said is implicated in fibrosis of the lung, liver and kidney. Gleevec was also shown to target the oxidoreductase NQO2. Kinobeads is a kinase-binding matrix that measures how compounds interact with about 300 different kinases. ...